Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys

Noventure is proud to announce the launch of XILAPLUS® in Estonia, Latvia and Lithuania by our partner company Miecys

XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies in adults, children, and infants.

XILAPLUS® is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments (CE 0373, Noventure SL).  It is part of the Noventure´s antidiarrheal mucoprotectors franchise, which is already being marketed in 40+ countries worldwide.

https://www.linkedin.com/company/jsc-miecys/?viewAsMember=true

https://www.linkedin.com/company/noventure/?viewAsMember=true